Shanghai Fosun Pharma paid $36 million to buy an older GlaxoSmithKline drug making facility in Suzhou, along with non-exclusive rights to manufacture lamivudine, a GSK treatment for hepatitis B/HIV. Last week, GSK officially opened a new $95 million Singapore facility that uses an enzyme-based continuous manufacturing process. The process is less expensive and more friendly to the environment than traditional chemical synthesis. Initially, GSK's new facility will produce Daprodustat, an oral treatment for anemia associated with chronic kidney disease. More details....
Stock Symbols: (SHA: 600196; HK: 2196) (NYSE: GSK)
Share this with colleagues: